Lens Concept has completed a purchase price allocation
March 2026 — Lens Concept has been acquired by MAE Pharma B.V. Following the acquisition, MAE Pharma was required to perform a purchase price allocation (PPA) to identify and value Lens Concept’s intangible assets and goodwill.
Lens Concept is a Netherlands-based wholesaler and distributor of private label eye care products. The company specializes in developing customized private label concepts for retailers and offers a broad portfolio including contact lenses, color lenses, eye drops, contact lens cleaning solutions, lens cases and reading glasses. Through its focus on private label development, Lens Concept enables optical retailers and other eye care distributors to expand their own branded product ranges and strengthen their position in the eye care market.
MAE Pharma is a manufacturer and distributor specializing in private label self-care products, cosmetics and health products. With more than 20 years of experience in pharmaceuticals and healthcare, the company provides self-care products with a medical identity and offers a wide range of generic medications.
Our role in the transaction
Oaklins’ team in the Netherlands advised during the post-transaction phase and prepared a PPA report for MAE Pharma in accordance with International Financial Reporting Standard 3 (IFRS 3). The report included the allocation of the consideration paid to all identifiable assets acquired and liabilities assumed.
Talk to the deal team
Related deals
Mattina Holding has sold a 5% stake in Gens Aurea via accelerated bookbuild
Mattina Holding S.A. (DVC Partners) has sold a 5% stake in Italian company Gens Aurea S.p.A. through an accelerated bookbuild, raising approximately US$69.96 million.
Learn moreTNT has been acquired by PM Studio
TNT Group has been acquired by PM Studio Group, backed by Andera Partners, bringing together two complementary specialists in premium packaging for the beauty and luxury industries. TNT’s expertise in bespoke primary packaging complements PM Studio’s secondary packaging, gifting and creative design capabilities, creating a broader, integrated offering for major luxury brands. The transaction strengthens the group’s geographical footprint in Asia and the USA, diversifying its customer portfolio. The combined group generates over US$145 million in revenue and has approximately 150 employees worldwide. Following the transition of operational leadership to CEO Damon Kennish, the founders completed the sale to PM Studio while making a significant reinvestment alongside the management team, demonstrating their confidence in the combined group’s long-term potential. It aims to reach US$280 million in revenue by 2029 through organic growth, commercial synergies and further acquisitions.
Learn moreKatalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn more